Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy

J Infect Dis. 2018 Jan 17;217(3):494-497. doi: 10.1093/infdis/jix564.

Abstract

As a live attenuated vaccine, yellow fever vaccine (YFV) is not routinely performed after allogeneic hematopoietic stem cell transplant (HSCT) despite it being the only efficient preventive therapy. We retrospectively identified 21 HSCT recipients immunized with YFV at a median of 39 months after HSCT and a median of 33 months after withdrawal of immunosuppression without any side effects. Eighteen evaluable patients had protective immunity after YFV. We also observed that a third of the recipients vaccinated with YFV before HSCT had persistent protective immunity after HSCT.

Keywords: allogeneic transplantation; immunocompromised; live attenuated vaccine; yellow fever.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunocompromised Host*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Transplantation, Homologous*
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / immunology
  • Yellow Fever / prevention & control*
  • Yellow Fever Vaccine / administration & dosage
  • Yellow Fever Vaccine / adverse effects*
  • Yellow Fever Vaccine / immunology*
  • Young Adult

Substances

  • Vaccines, Attenuated
  • Yellow Fever Vaccine